Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Hepatitis C Virus (HCV)
Interventions
BIOLOGICAL

Peginterferon Lambda-1a

DRUG

Ribavirin

BIOLOGICAL

Peginterferon alfa-2a

Trial Locations (16)

44500

Local Institution, Guadalajara

44650

Local Institution, Guadalajara

500 05

Local Institution, Hradec Králové

140 00

Local Institution, Prague

400 01

Local Institution, Ústí nad Labem

03720

Local Institution, Distrito Federal

07760

Local Institution, Mexico City

06700

Local Institution, México

330-930

Local Institution, Chungcheongnam-do

700-821

Local Institution, Daegu

200-704

Local Institution, Gangwon-do

420-717

Local Institution, Gyeonggi-do

463-707

Local Institution, Gyeonggi-do

626-770

Local Institution, Gyeongsangnam-do

403-720

Local Institution, Incheon

156-755

Local Institution, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01754974 - Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C | Biotech Hunter | Biotech Hunter